trial

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

NCTId NCT01263080
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 333 (actual)
Sponsored by Capital Medical University
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
333 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Double
Start
2010-11
Primary completion
2012-12
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
mirtazapineFolic Acid

Sponsors

Capital Medical UniversityLead Sponsor

Investigators

1
Gang Wang, M.D.Principal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
333
Phase
PHASE4
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
mirtazapine
drug
Folic Acid
drug
lead_sponsor
Capital Medical University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gang Wang, M.D.
person